Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Conditions:   Advanced Extrapulmonary Neuroendocrine Carcinoma;   Metastatic Extrapulmonary Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Neuroendocrine Carcinoma;   Unresectable Extrapulmonary Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Procedure: Biospecimen Collection;   Drug: Carboplatin;   Drug: Cisplatin;   Procedure: Computed Tomography;   Drug: Etoposide;   Procedure: Magnetic Resonance Imaging;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  2. Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT;   Drug: CAPTEM (Capecitabine and Temozolomide);   Other: Amino-Acid Solution;   Drug: Everolimus;   Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
    Sponsor:   ITM Solucin GmbH
    Recruiting
  3. Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  4. Condition:   Metastatic Neuroendocrine Tumor
    Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Lutetium Lu 177 Dotatate;   Procedure: Magnetic Resonance Imaging;   Drug: Triapine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  5. Condition:   Advanced Neuroendocrine Carcinoma
    Interventions:   Drug: Surufatinib plus Toripalimab;   Drug: 5-fluorouracil, Calcium folinate and Irinotecan
    Sponsor:   Hutchison Medipharma Limited
    Recruiting
  6. Conditions:   Neuroendocrine Carcinoma;   Digestive Cancer
    Interventions:   Drug: Neoadjuvant treatment;   Drug: Adjuvant treatment
    Sponsors:   GERCOR - Multidisciplinary Oncology Cooperative Group;   Fondation ARCAD
    Recruiting
  7. Conditions:   Advanced Lung Carcinoid Tumor;   Functioning Lung Carcinoid Tumor;   Locally Advanced Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Typical Carcinoid Tumor;   Metastatic Lung Carcinoid Tumor;   Metastatic Lung Neuroendocrine Neoplasm;   Non-Functioning Lung Carcinoid Tumor;   Recurrent Lung Neuroendocrine Neoplasm;   Unresectable Lung Carcinoid Tumor;   Unresectable Lung Neuroendocrine Neoplasm
    Interventions:   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  8. Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
    Interventions:   Drug: Olaparib;   Drug: Durvalumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  9. Conditions:   Small Cell Neuroendocrine Carcinoma;   Prostate Cancer;   Small Cell Carcinoma
    Interventions:   Drug: Apalutamide;   Biological: Cetrelimab
    Sponsors:   Rahul Aggarwal;   Janssen Scientific Affairs, LLC
    Recruiting
  10. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Digestive System Neuroendocrine Neoplasm;   Locally Advanced Digestive System Neuroendocrine Tumor G1;   Locally Advanced Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Lung Carcinoid Tumor;   Metastatic Lung Neuroendocrine Neoplasm;   Metastatic Pancreatic Neuroendocrine Neoplasm;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Thymic Carcinoid Tumor;   Unresectable Digestive System Neuroendocrine Neoplasm;   Unresectable Digestive System Neuroendocrine Tumor G1;   Unresectable Lung Neuroendocrine Neoplasm;   Unresectable Pancreatic Neuroendocrine Neoplasm;   Unresectable Thymic Neuroendocrine Neoplasm
    Interventions:   Drug: Cabozantinib S-malate;   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Procedure: X-Ray Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  11. Conditions:   Metastatic Midgut Neuroendocrine Tumor;   Unresectable Midgut Neuroendocrine Tumor
    Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  12. Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor;   Von Hippel-Lindau Disease;   Advanced Gastrointestinal Stromal Tumor;   HIF-2α Mutated Cancers
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting
  13. Condition:   Neuroendocrine Carcinoma
    Intervention:   Drug: Surufatinib and Serplulimab
    Sponsor:   Wuhan Union Hospital, China
    Not yet recruiting
  14. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning;   Drug: Amino Acid infusion
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  15. Conditions:   Prostate Cancer;   Neuroendocrine Tumors;   Small Cell Carcinoma
    Interventions:   Drug: BXCL701 plus Pembrolizumab;   Drug: BXCL701 monotherapy
    Sponsor:   BioXcel Therapeutics Inc
    Recruiting
  16. Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  17. Conditions:   HRD Cancer;   SCLC;   Advanced Solid Tumors
    Interventions:   Drug: Berzosertib;   Drug: Sacituzumab Govitecan
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  18. Conditions:   Lung Neuroendocrine Neoplasm;   GEP Neuroendocrine Tumor
    Intervention:   Drug: Cabozantinib and Temozolomide
    Sponsor:   National Cancer Institute, Naples
    Recruiting
  19. Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Cancer;   Poorly Differentiated Neuroendocrine Carcinomas;   Homologous Recombination Deficient-Positive Malignancies Agnostic
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  20. Conditions:   NSCLC;   SCLC;   High Grade Neuroendocrine Cancer;   DLBCL;   L-MYC and N-MYC Amplified Solid Tumors;   NSCLC With High or Low L-MYC or N-MYC Expression;   SCLC With High or Low L-MYC or N-MYC Expression
    Intervention:   Drug: Oral MRT-2359
    Sponsor:   Monte Rosa Therapeutics, Inc
    Recruiting
  21. Conditions:   Solid Tumor;   Non Small Cell Lung Cancer;   Neuroendocrine Carcinoma
    Interventions:   Biological: VSV-IFNβ-NIS;   Biological: Pembrolizumab
    Sponsors:   Vyriad, Inc.;   Mayo Clinic
    Recruiting
  22. Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  23. Condition:   Traumatic Injury of the Spinal Cord
    Intervention:   Drug: HBO
    Sponsor:   Medical University of Graz
    Recruiting
  24. Condition:   Binge-eating Disorder
    Interventions:   Drug: TNX-1900 (Tonix Pharmaceuticals);   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting
  25. Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Invasive Bladder Giant Cell Urothelial Carcinoma;   Invasive Bladder Lymphoepithelioma-Like Carcinoma;   Invasive Bladder Nested Urothelial Carcinoma;   Invasive Bladder Plasmacytoid Urothelial Carcinoma;   Invasive Bladder Sarcomatoid Urothelial Carcinoma;   Invasive Bladder Urothelial Carcinoma;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Malignant Testicular Leydig Cell Tumor;   Malignant Testicular Sertoli Cell Tumor;   Metastatic Bladder Carcinoma;   Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma;   Metastatic Bladder Giant Cell Urothelial Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Lipid-Rich Urothelial Carcinoma;   Metastatic Bladder Micropapillary Urothelial Carcinoma;   Metastatic Bladder Plasmacytoid Urothelial Carcinoma;   Metastatic Bladder Sarcomatoid Urothelial Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Chromophobe Renal Cell Carcinoma;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Papillary Renal Cell Carcinoma;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Urachal Adenocarcinoma;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Procedure: Bone Scan;   Drug: Cabozantinib S-malate;   Procedure: Computed Tomography;   Biological: Ipilimumab;   Procedure: Magnetic Resonance Imaging;   Biological: Nivolumab;   Procedure: Positron Emission Tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  26. Conditions:   Aggressive Variant Prostate Carcinoma;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Prostate Neuroendocrine Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Stage IV Prostate Cancer AJCC v8
    Interventions:   Drug: Cabazitaxel;   Drug: Carboplatin;   Biological: Cetrelimab;   Drug: Niraparib
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Pharmaceutica
    Recruiting
  27. Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting
  28. Conditions:   Endocrine/Neuroendocrine;   Non-Small Cell Lung Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Ovarian Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Biological: Sleeping Beauty Transposed PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  29. Conditions:   Endocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Neuroendocrine Tumors;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL;   Drug: Pembrolizumab (KEYTRUDA )
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  30. Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Ampullary Cancer;   Pancreas Neuroendocrine Tumor;   Pancreatitis;   Distal Extrahepatic Cholangiocarcinoma;   Duodenal Cancer
    Interventions:   Drug: Placebo;   Drug: Pantoprazole
    Sponsor:   Washington University School of Medicine
    Recruiting
  31. Conditions:   Colorectal Cancer Not MSI-H or MMR-deficient;   GIST;   Oesophageal or Gastric Carcinoma;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Soft-tissue Sarcoma;   Thyroid Cancer;   Gastro-enteropancreatic Neuroendocrine Tumor;   Non-small Cell Lung Cancer;   Solid Tumor, Adult;   Urothelial Carcinoma;   HPV-Related Carcinoma;   Triple Negative Breast Cancer;   Renal Carcinoma;   Mesotheliomas Pleural
    Interventions:   Drug: Phase 1 : Regorafenib;   Drug: Phase 1 : Avelumab;   Drug: Phase 2 : Regorafenib;   Drug: Phase 2 : Avelumab;   Drug: Phase 2: low-dose Regorafenib
    Sponsors:   Institut Bergonié;   Bayer;   Merck KGaA, Darmstadt, Germany
    Recruiting
  32. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Pralsetinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsor:   Hoffmann-La Roche
    Recruiting
  33. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  34. Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting
  35. Conditions:   Carcinoid Syndrome;   Carcinoid;   Carcinoid Tumor;   Carcinoid Tumor of Ileum;   Carcinoid Tumor of Cecum;   Carcinoid Syndrome Diarrhea;   Carcinoid Intestine Tumor;   Carcinoid Tumor of Liver;   Carcinoid Tumor of Pancreas
    Interventions:   Drug: Randomized: 40 mg Paltusotine;   Drug: Randomized: 80 mg Paltusotine
    Sponsor:   Crinetics Pharmaceuticals Inc.
    Recruiting
  36. Condition:   Small-cell Lung Cancer
    Interventions:   Drug: HPN328;   Drug: Atezolizumab
    Sponsor:   Harpoon Therapeutics
    Recruiting
  37. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  38. Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg;   Drug: Olaparib 300 mg;   Drug: Abiraterone acetate 1000 mg;   Drug: Lenvatinib;   Biological: Pembrolizumab/Vibostolimab coformulation;   Drug: Carboplatin;   Drug: Etoposide;   Biological: Belzutifan 120mg
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting
  39. Conditions:   Atypical Teratoid/Rhabdoid Tumor;   Epithelioid Sarcoma;   Kidney Medullary Carcinoma;   Malignant Solid Neoplasm;   Poorly Differentiated Chordoma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Chordoma;   Recurrent Epithelioid Sarcoma;   Recurrent Kidney Medullary Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Rhabdoid Tumor;   Refractory Atypical Teratoid/Rhabdoid Tumor;   Refractory Chordoma;   Refractory Epithelioid Sarcoma;   Refractory Kidney Medullary Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Rhabdoid Tumor;   Rhabdoid Tumor
    Interventions:   Biological: Atezolizumab;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Other: Fludeoxyglucose F-18;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography;   Biological: Tiragolumab;   Procedure: X-Ray Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  40. Conditions:   Adrenal Gland Pheochromocytoma;   Hematopoietic and Lymphoid System Neoplasm;   Malignant Solid Neoplasm;   Paraganglioma
    Interventions:   Procedure: Computed Tomography;   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  41. Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  42. Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Recruiting
  43. Conditions:   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of the Lung;   Merkel Cell Carcinoma;   Myxoid/Round Cell Liposarcoma
    Intervention:   Biological: CAR-GPC3 T Cells
    Sponsors:   SOTIO, LLC;   SOTIO Biotech
    Recruiting
  44. Condition:   Merkel Cell Carcinoma
    Interventions:   Drug: KRT-232;   Drug: Avelumab
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting
  45. Conditions:   Metastatic Cancer;   Foregut Carcinoid Tumor;   Gastric Adenocarcinoma;   Gallbladder Adenocarcinoma;   Liver Cancer;   GI Cancer;   GI Carcinoma;   Lung Cancer
    Interventions:   Drug: Standard of Care Chemotherapy;   Procedure: Video-Assisted Thoracic Surgery (VATS);   Procedure: Lobectomy;   Radiation: Consolidative Radiation;   Radiation: Ablation Treatment;   Procedure: Resection or Excision;   Procedure: Peritonectomy;   Other: Transarterial Radioembolization
    Sponsor:   University of Chicago
    Not yet recruiting
  46. Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Choriocarcinoma;   Embryonal Carcinoma;   Immature Teratoma;   Malignant Teratoma;   Mixed Germ Cell Tumor;   Pineal Region Germ Cell Tumor;   Pineal Region Immature Teratoma;   Pineal Region Yolk Sac Tumor;   Suprasellar Germ Cell Tumor
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Mesna;   Biological: Pegfilgrastim;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Procedure: Second-Look Surgery;   Drug: Thiotepa
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting